ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study
Investors Seem Wary Of Its Prospects, However
Executive SummaryCompany terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
You may also be interested in...
Repurposing a TORC1 inhibitor investigated in several cancer types at Novartis, resTORbio has initiated a second Phase III study of RTB101 to address immunosenescence in older adults. CMO Joan Mannick discusses R&D strategy in interview at IDWeek.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.